Key result
DDX56 overexpression increased FMDV replication by cooperating with FMDV 3A to inhibit type I interferon through reduced phosphorylation of IRF3.
Why the study?
Whether host proteins other than 3A, 2C, and 2B interact with foot-and-mouth disease virus components to impact viral replication was less understood.
DDX56 acts as a positive regulator of FMDV replication by cooperating with viral protein 3A to inhibit the host type I interferon response.
Answers are grounded in this paper and cite their sources.
Animal data identify DDX56 as proviral for FMDV; hypothesis-generating for host-targeted antivirals pending in vivo validation.
The components of foot-and-mouth disease virus (FMDV) interact with host cellular proteins to promote self-replication and evade the host immune response. Previous studies have shown that FMDV 3A, 2C and 2B proteins interact with host cellular proteins involved in FMDV replication. However, whether the other host proteins have an impact on FMDV replication is less understood. In this study, we identified DDX56 as a positive regulator of FMDV replication. DDX56 overexpression increased FMDV replication, whereas DDX56 knockdown had the opposite effect. DDX56 interacted and cooperated with FMDV 3A to inhibit the type I interferon by reducing the phosphorylation of IRF3. Moreover, the D166 site of DDX56 played a role in increasing FMDV replication and cooperating with FMDV 3A to inhibit the phosphorylation of IRF3. Additionally, knockdown of DDX56 or FMDV 3A results also showed that DDX56 cooperated with FMDV 3A to inhibit the phosphorylation of IRF3. These results suggest that the interaction between FMDV 3A protein and the host protein DDX56 is critical for FMDV replication.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2019) studied Foot-and-mouth disease virus (FMDV) infection. DDX56 overexpression and knockdown was evaluated on FMDV replication and IRF3 phosphorylation. DDX56 overexpression increased FMDV replication by cooperating with FMDV 3A to inhibit type I interferon through reduced phosphorylation of IRF3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: